Table 4. Multiple Proportional Hazards Regression Models* for Local-Regional Failure and Overall Survival.
| Local-Regional Failure* | |||
|---|---|---|---|
|
| |||
| Parameter | Comparison | Hazard Ratio (95% CI**) | p-value |
| BED | Continuous | 0.98 (0.97, 0.99) | <0.0001 |
| Age | Continuous | 0.77 (0.61, 0.99) | 0.04 |
| Gender | Female vs. Male | RL 1.32 (1.12, 1.55) | 0.0008 |
| KPS | 90-100 vs. 70-80 | RL 1.06 (0.89, 1.27) | 0.52 |
| Histology | Non-Squamous vs. Squamous | RL 1.04 (0.89, 1.21) | 0.61 |
| Stage Group | II/IIIA vs. IIIB | RL 1.17 (1.00, 1.36) | 0.04 |
| RT Delivery Method | HFX vs. SFX | RL 1.08 (0.93, 1.25) | 0.33 |
| Chemotherapy | Sequential vs. Induction | RL 1.28 (1.09, 1.51) | 0.003 |
|
| |||
| Parameter | Comparison | Hazard Ratio (95% CI**) | p-value |
|
| |||
| tBED | Continuous | 0.97 (0.96, 0.98) | <0.0001 |
| Age | Continuous | 0.76 (0.60, 0.97) | 0.03 |
| Gender | Female vs. Male | RL 1.34 (1.13, 1.57) | 0.0005 |
| KPS | 90-100 vs. 70-80 | RL 1.06 (0.89, 1.27) | 0.5 |
| Histology | Non-squamous vs. Squamous | RL 1.05 (0.90, 1.22) | 0.54 |
| Stage Group | II/IIIA vs. IIIB | RL 1.16 (1.003, 1.35) | 0.045 |
| Chemotherapy sequence | Sequential vs. Induction | RL 1.35 (1.15, 1.60) | 0.0003 |
|
| |||
| Overall Survival | |||
|
| |||
| Parameter | Comparison | Hazard Ratio (95% CI**) | p-value |
|
| |||
| BED | Continuous | 0.97 (0.96, 0.98) | <0.0001 |
| Age | Continuous | 1.19 (1.02, 1.41) | 0.03 |
| Gender | Female vs. Male | RL 1.14 (1.01, 1.29) | 0.03 |
| KPS | 90-100 vs. | RL 1.22 (1.07, 1.40) | 0.003 |
| Histology | Non-squamous vs. squamous | RL 1.15 (1.02, 1.29) | 0.02 |
| Stage Group | II/IIIA vs. IIIB | RL 1.13 (1.01, 1.26) | 0.04 |
| RT Delivery Method | HFX vs. SFX | RL 0.94 (0.84, 1.06) | 0.31 |
| Chemotherapy sequence | Sequential vs. Induction | RL 1.24 (1.09, 1.41) | 0.0009 |
|
| |||
| Parameter | Comparison | Hazard Ratio (95% CI**) | p-value |
|
| |||
| tBED | Continuous | 0.97 (0.96, 0.98) | <0.0001 |
| Age | Continuous | 1.16 (0.99, 1.37) | 0.07 |
| Gender | Female vs. Male | RL 1.16 (1.03, 1.31) | 0.02 |
| KPS | 90-100 vs. 70-80 | RL 1.25 (1.10, 1.43) | 0.0009 |
| Histology | Non-squamous vs. Squamous | RL 1.15 (1.02, 1.29) | 0.02 |
| Stage Group | II/IIIA vs. IIIB | RL 1.16 (1.04, 1.30) | 0.009 |
| Chemotherapy sequence | Sequential vs. Induction | RL 1.29 (1.14, 1.47) | <0.0001 |
*
Fine and Gray's Proportional Hazards Regression Model was used for LRF and Cox Proportional Hazards Regression was for OS.
**
CI=Confidence Interval; RL=Reference Level